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Abstract
Prostaglandins (PGs) are requisite components of inflammatory pain as indicated by the efficacy of
cyclooxygenase 1/2 (COX1/2) inhibitors. PGs do not activate nociceptive ion channels directly, but
sensitize them by downstream mechanisms linked to G-protein coupled receptors.
Antiinflammatory effects are purported to arise from inhibition of synthesis and/or release of
proinflammatory agents. Release of these agents from peripheral and central terminals of sensory
neurons modulates nociceptive input from the periphery and synaptic transmission at the first
sensory synapse, respectively. Heart and blood vessels are densely innervated by sensory nerve
endings that express chemo-, mechano-, and thermo-sensitive receptors. Activation of these
receptors mediates synthesis and/or release of vasoactive agents by virtue of their
Ca2+permeability. In this article, we discuss that inhibition of COX2 reduces PG synthesis and
renders beneficial effects by preventing sensitization of nociceptors, but at the same time, it might
contribute to deleterious cardiovascular effects by compromising the synthesis and/or release of
vasoactive agents.
Synthesis and functions of arachidonic acid and 
its metabolites
Arachidonic acid (AA) and its metabolites are involved in
several important cardiovascular functions. In this article,
we address the adverse cardiovascular effects that arise as
a result of block of PG mediated modulation of nocicep-
tive ion channels. AA is produced from membrane phos-
pholipids by phospholipase A2  (PLA2), a calcium-
dependent enzyme, which is activated by proinflamma-
tory agents and shear stress exerted on the vessel wall.
Activation of phospholipase C (PLC) hydrolyzes phos-
phatidyl inositol 4, 5 bisphosphate (PIP2) to inositol 1, 4,
5 trisphosphate (IP3) and diacyl glycerol (DAG). DAG
activates protein kinase C (PKC) and DAG lipase, activa-
tion of DAG lipase can in turn produce AA. Activation of
phospholipase D produces anandamide, which can sub-
sequently be converted to AA by fatty acid amide hydro-
lase [1].
AA is metabolized via cyclooxygenase (COX1/2), lipoxy-
genase (5, 12, 15, LOX) and cytochrome P450 (CYP)
pathways. COX1 is constitutively active, whereas COX2 is
inducible, except in the kidneys and in some parts of cen-
tral nervous system, where it is expressed constitutively
[2]. Cyclooxygenase activation produces prostaglandin H2
(PGH2), which is subsequently metabolized to PGD2,
PGE2, PGF2α, PGI2 and thromboxane A2 (TxA2) [1].
Initial lipoxygenase products 5, 8, 12 and 15-(S)
hydroperoxyeicosatetraenoic acids (HPETEs) are subse-
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quently metabolized to 5, 8, 12, 15-(S) hydroxyeicosa-
tetraenoic acids (HETEs). 5-HETE is metabolized to
leukotriene A4 (LTA4), which can be converted to other
leukotrienes (LTB4-E4). LTA4  can also be converted to
lipoxins by 12- and 15-LOX. AA can also undergo ω-
hydroxylation by several isoforms of CYP enzymes lead-
ing to the production of 19- and 20-HETE. Several fami-
lies of CYP also convert AA into epoxyeicosatrienoic acids
(EETs) [1] (Fig. 1). The distribution, coupling mecha-
nisms and actions of AA metabolites on cardiovascular
system are shown in Table 1.
Role of sensory innervation in the cardiovascular 
system
Noxious stimuli are transduced by peripheral nociceptors,
which transmit nociceptive information to pain process-
ing centers in the brain via the spinal cord. Heart and
blood vessels are densely innervated by sensory nerve
endings that express chemo-, mechano-, and thermo-sen-
sitive receptors, which include acid sensitive ion channels
(ASIC), degenerin/epithelial sodium channels (DEG/
ENAC), purinergic ATP gated ion channels (P2X), and
transient receptor potential (TRP) channels [3-7]. Activa-
tion of nociceptive ion channels, particularly ASIC3 and
TRPV1, has been implicated in ischemic cardiac pain [5].
Both these channels can be activated by acidic pH and
sensitized by proinflammatory agents synthesized and/or
released during ischemia.
Activation of Ca2+ permeant nociceptive ion channels on
the peripheral and central terminals of sensory neurons
leads to the synthesis and/or release of a variety of proin-
flammatory agents and neuropeptides, like bradykinin
(BK), PGs, calcitonin gene-related peptide (CGRP), sub-
stance P (SP), vasoactive intestinal peptide (VIP) and ade-
nosine triphosphate (ATP) etc. [8,9]. Increases in
intracellular Ca2+ initiate several second messenger path-
ways, including activation of PLA2, PLC and Ca2+-depend-
Schematic diagram showing the pathways involved in synthesis and metabolism of AA Figure 1
Schematic diagram showing the pathways involved in synthesis and metabolism of AA.
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ent kinases, which can lead to the generation of AA and its
metabolites, release of Ca2+ from intracellular stores, and
phosphorylation of nociceptive receptors, respectively. BK
is thought to be synthesized and released on demand
from sympathetic nerve endings [11]. BK initiates prosta-
noid synthesis and mediates release of vasoactive neu-
ropeptides [10,11]. PGE2  and PGI2  are produced in
response to nociceptive stimuli and lead to inflammation
and pain by sensitization of nociceptors. PGI2 is a potent
vasodilator and platelet deaggregator [12]. In blood ves-
sels, activation of nociceptive receptors results in an
endothelium independent vasodilatory response, which
is mediated mainly by the release of CGRP [13]. CGRP is
a potent vasodilator (coronary vasculature is particularly
sensitive) that increases both heart rate and contractile
force [13,14]. SP and VIP released from sensory nerve ter-
minals induce vasodilation and positive chronotropic
effect [15]. ATP is released ubiquitously along with neuro-
transmitters and induces vasoconstriction by activation of
P2X receptors, however, its breakdown product adenosine
is a potent vasodilator and also inhibits neurotransmitter/
neuropeptide release [16]. Relatively less prominent
vasoactive agents are also released from the nociceptive
nerve endings including galanin, corticotrophin-releasing
factor, arginine, cholecystokinin-octapeptide, neuropep-
tide K, eledoisin-like peptide and bombesin-like peptides
[14]. Nociceptor stimulation not only serves as a sensory-
afferent, but also plays a significant role in sensory-effer-
ent functions [8]. It has also been postulated that vascular
regulation via an efferent mechanism could be independ-
ent of the sensory afferent function [17] and the selective
synthesis and/or release of specific vasoactive agents could
arise from the nature of the stimulus and/or its intensity
[18]. Thus, activation of Ca2+ permeable nociceptive ion
channels at the peripheral and central terminals of sen-
sory neurons can play an important role in the synthesis
and/or release of vasoactive agents.
Nociceptive ion channels in cardiovascular 
system
Several nociceptive ion channels have been cloned. Most
of these channels are modulated by PKA and PKC medi-
ated phosphorylation. Significantly, PGE2 and PGI2 medi-
ate their effects by activation of PKA and PKC pathways.
The Transient Receptor Potential (TRP) channels (TRPVa-
nilloid, TRPAnkyrin, TRPClassical, and TRPMelastatin)
Table 1: Cardiovascular functions of AA and its metabolites
AA Metabolite Receptor subtypes Secondary messenger 
mechanisms
Tissue distribution of the receptors Cardiovascular functions of AA 
metabolites
Ref.
PGD2 DP1, DP2 (CRTH2) Gs (DP1, 2), Gi, Gq, 
MAPK (DP2)
Leptomeninges, Langerhan cells, 
Goblet and columnar cells in GI 
tract, Eosinophils for DP1, All 
tissues for DP2
Vasodilation, Vasoconstriction, 
Platelet deaggregation
1, 12
PGE2 EP1, EP3, EP3, EP4 Gs, Gi, Gq Kidney, Lung and Stomach for EP1, 
EP2 expressed in response to LPS 
and gonadotrophins, EP3 and 4 in all 
tissues
Vasodilation, Vasoconstriction, 
Maintain renal blood flow and 
GFR, Vascular smooth muscle 
mitogenesis
1, 12, 
15
PGI2 IP Gs (predominant), Gi, 
Gq
Neurons, (primarily DRGs), 
Endothelial cells, Vascular smooth 
muscle cells, Kidney, Thymus, 
Spleen and Megakaryocytes
Vasodilation, Inhibit platelet 
aggregation, Inhibit TXA2-
induced vascular proliferation
1, 12, 
21, 58
PGF2α FP Gq, EGFR Corpus luteum, Kidney, Heart, Lung 
and Stomach
Vasoconstriction, Mitogenesis 
in heart, Inflammatory 
tachycardia, Renal functions
1, 12
TXA2 TP Gq, Gs, Gi, Gh, G12 Kidney, Heart, Lungs, Platelets and 
Immune cells
Platelet aggregation, 
Vasoconstriction, Inflammatory 
tachycardia
1, 12, 
58
20-HETE ? Gq, Tyrosine kinase, 
Increased 
conductance of L-type 
Ca2+ channels, 
Inhibition of Na+-K+-
2Cl cotransporter
? Renal and cerebral artery 
contraction, Antagonize EDHF 
mediated vasorelaxation, 
Myogenic constriction, 
Regulate renal functions
1, 54
Leukotrienes 
(LTB4-E4)
BLT1, BLT2 (LTB4), 
CysLT1, CysLT2 
(LTC4-D4)
?Gi/Go (BLT1,2, 
CysLT1,2), Gα16 
(BLT1,2)
Leukocytes, spleen, thymus, bone 
marrow, lymph nodes, heart, 
skeletal muscle, brain and liver for 
BLT1, Most tissues for BLT2,
Coronary smooth muscle 
contraction, Transient 
pulmonary and systemic 
hypertension
1, 54
EETs ? Gs, Tyrosine kinases, 
ERK1/2, p38 MAPK, 
Activation of Ca2+-
activated K+ channels
? Renal and cerebral vasodilation, 
Renal vasoconstriction, 
Vascular smooth muscle and 
endothelial cell proliferation
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are chemo-, mechano-, and thermo-sensitive. TRPV1 is a
well-characterized channel, which transduces heat in the
noxious temperature range (>42°C) and is critical for
inflammatory thermal sensation [19]. It is a Ca2+ per-
meant polymodal receptor activated by protons, ananda-
mide, lipoxygenase metabolites of AA, N-arachidonyl
dopamine, capsaicin (an active ingredient in hot chilli
peppers) and resiniferatoxin (RTX, an ultrapotent agonist
obtained from the cactus, Euphorbia resinifera) [20].
TRPV1 is distributed in the heart and blood vessels and is
sensitized by PGs via PKA and PKC mediated phosphor-
ylation [21]. Importantly, in the phosphorylated state, the
activation threshold of TRPV1 is reduced below body tem-
perature rendering the channel constitutively active [20].
Furthermore, phosphorylation also promotes transloca-
tion of TRPV1 from the cytosol to the plasma membrane
[22,23]. Activation of TRPV1 in sensory nerve endings
supplying heart and blood vessels releases multiple
vasoactive agents [14]. In diabetes, TRPV1 has been
shown to be downregulated, which might contribute to
the cardiovascular complications [23].
The role of TRPV1 in the cardiovascular system has been
addressed: 1) Infusion of TRPV1 agonists significantly
alters blood pressure, which could be mostly reversed by
selective TRPV1 antagonists [24,25]; 2) Ablation of TRPV1
expressing C fiber terminals by capsaicin or resinifera-
toxin (RTX) results in the loss of CGRP release, increased
plasma renin activity, and an inability to control salt load-
ing by the kidneys [14]; 3) Activation of TRPV1 or ASIC3
by protons during ischemia mediates a sympathoexcita-
tory reflex that is abolished by RTX treatment [5,26].
Inhibition of COX leads to increased metabolism of AA
via LOX and CYP pathways. Products of LOX pathway
(12- and 15-(S)-HPETE, 5- and 15-(S)-HETEs and LB4)
can directly gate TRPV1 [20]. Myogenic constriction in
response to increased pressure on the intraluminal surface
of blood vessels is mediated by the CYP byproduct 20-
HETE, which directly activates TRPV1 and releases SP [27].
We propose that reduction of PG levels may contribute to
deleterious vascular effects by decreasing sensitization of
TRPV1 and subsequent reduction of CGRP and SP release.
This possibility is supported by the finding that recovery
from myocardial ischemia is compromised in TRPV1
knockout mice [28] and proton mediated CGRP release
from the heart is mediated exclusively by TRPV1 [29,30].
Since TRPV1 antagonists may become a part of the thera-
peutic armamentarium for painful conditions [31], it is
imperative to determine if blocking nociceptive receptors
like TRPV1 decreases the release of vasoactive agents that
are essential for homeostasis of the cardiovascular system.
TRPV2 is 50% identical to TRPV1 and mediates high-
threshold (>52°C) noxious heat sensation. In arterial
myocytes, TRPV2 is activated by stretch, which is an
important stimulus in cardiovascular functions [32]. Car-
diac-specific transgene expression of TRPV2 results in
Ca2+-overload-induced cardiomyopathy [32]. TRPV3 is
activated by temperatures >31°C and is involved in noci-
ception [32]. TRPV4 is activated by temperatures >25°C
and its activity is augmented by hypotonicity. PGE2 poten-
tiates TRPV4 and exacerbates pain behavior in animals,
whereas EET directly activates the channel [32,33]. TRPV4
is found abundantly on endothelial and vascular smooth
muscle cells of intralobar pulmonary artery and aorta
where, it mediates calcium influx [34]. TRPM8 is a Ca2+
permeant innocuous cold temperature sensor, which
plays a role in nociception [36] and mediates Ca2+ influx
into vascular smooth muscle cells [34].
Mechanosensitive channels play a major role in cardiovas-
cular functions and the identity of these channels is
becoming apparent with cloning of TRPC1 and TRPA1
[32]. TRPC1, 2, 3, 4 and 6 are present on endothelial cells,
activation of which increases intracellular Ca2+ [35]. DEG/
ENAC belongs to a family of mechanosensitive channels,
which include ASICs and their splice variants [37]. ASICs
are modulated by AA, PKC and PKA [37-41]. ASIC1
behaves as a mechanosensor only in viscera, but not in the
periphery [42,43]. Activation of ASIC3 has been postu-
lated to carry ischemic cardiac pain [5].
Chemo-sensitive purinergic receptors (P2X1–6) are acti-
vated by extracellular ATP. The P2X3 receptor subtype is
expressed exclusively in small and medium diameter dor-
sal root and trigeminal ganglia neurons [44]. In the cardi-
ovascular system, activation of P2X4 receptor increases
cardiac contractility [45]. Activation of P2X mediates AA
production via stimulation of PLA2 [46]. P2X1,2,7 channels
are also regulated by PKC [47-49]. P2X1 is present on vas-
cular smooth muscle cells and mediates vasoconstriction
by ATP released from sympathetic nerve activity [50].
From these studies it is clear that several nociceptive ion
channels are modulated by activation of PKA and PKC,
therefore, it is reasonable to expect that PGs coupled to
these pathways would be able to sensitize the nociceptive
ion channels. Thus, in our opinion, it is highly probable
that the block of PG synthesis by COX inhibitors affects
the cardiovascular functions mediated by nociceptive ion
channels (Fig. 2).
Advantages and disadvantages of selective 
inhibition of COX2
Although COX2 inhibitors have become popular, their
analgesic effects are comparable to non-specific COX
inhibitors [51]. The selectivity of COX2 inhibitors has aMolecular Pain 2006, 2:26 http://www.molecularpain.com/content/2/1/26
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significant advantage of avoiding gastrointestinal side
effects (VIGOR study) due to the preservation of PGE2 lev-
els and a reduction in the incidence of colon cancer by
inhibition of PG-mediated angiogenesis [52-54]. The
inducible nature of COX2 is claimed to have significant
advantages because it is activated only at the sites of
inflammation. In this regard, it is significant to note that
atherosclerotic lesions are inflammatory in nature [55]
and PGI2 (vasodilator, platelet deaggregator and sensitizer
of nociceptive receptors) is synthesized via COX2 activa-
tion as a necessary protective mechanism. Nonspecific
COX inhibitors decrease production of both, PGI2 and
TxA2 (platelet aggregator), thereby avoiding an imbalance
between PGI2 and TxA2 levels [56]. In contrast, when
COX2 is inhibited selectively, platelet aggregation by TxA2
is intact, but at the same time PGI2 induced platelet deag-
gregation is compromised, resulting in enhanced platelet
aggregation [57]. Here, we propose that inhibition of
PGE2 and PGI2 could also reduce sensitization of nocicep-
tors and compromise release of potent vasodilators in
response to ischemia, which could be critical in reversing
hypoperfusion in conditions like myocardial ischemia.
Indeed, injury-induced platelet activation is enhanced in
PGI2 receptor (IP) knock-out mice [58], whereas it is
reduced in TxA2 receptor (TP) knock-out mice [58]. These
findings are consistent with patients treated with COX2
inhibitors suffering from higher incidence of MI and
stroke as compared to naproxen treated patients
[53,59,60]. A combination of a COX2 and a low dose of
COX1 inhibitors (for example, 80 mgs of aspirin) may be
Second messenger pathways that modulate nociceptive ion channels Figure 2
Second messenger pathways that modulate nociceptive ion channels.
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a beneficial strategy to prevent TxA2-mediated platelet
aggregation. Furthermore, the need for platelet deaggrega-
tion becomes even more critical, given the lifetime risk of
developing atrial fibrillation significantly increases over
40 years of age [61], which can initiate thromboembo-
lism.
Concluding remarks and future directions
The beneficial effects of COX inhibitors are derived from
their ability to inhibit synthesis of PGs. However, several
important cardiovascular functions mediated by PGs are
compromised, including direct vasodilation, vasocon-
striction, and platelet aggregation/deaggregation. Herein,
we propose that the ability of PGs to sensitize nociceptive
ion channels involved in the release of potent vasoactive
agents could also be compromised. A well-characterized
receptor in this context is TRPV1, which is sensitized by
PGs and its activation mediates the synthesis and/or
release of vasoactive agents by virtue of its high Ca2+ per-
meability. TRPV1 is currently being pursued as a potential
target for the next generation of analgesics [31]. Use of
COX inhibitors should be dictated objectively by under-
standing the mechanisms by which cardiovascular com-
plications are induced, instead of being swayed by
emotional testimonies in congressional inquires. Drug
industries would be better advised to invest in research
rather than spending billions (3 billion in 2004) in adver-
tising and direct marketing to patients. Judicious use of
these drugs with open dialogue between drug industries,
physicians and patients must be encouraged, so that all
the parties involved can make an informed decision, fully
aware of the consequences. Patients who are in the right
category would benefit from these drugs, while sparing
others who are at a risk for cardiovascular complications.
This strategy/approach will also avoid expensive class
action lawsuits and prevent driving the cost of medication
higher; otherwise, patients who need the medication most
may not be able to afford.
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